Paul Santerre

Joseph Paul Patrice-Guy Santerre (born 1960) is a Canadian engineer. He is a Full Professor at the University of Toronto and holds the Baxter Chair in Health Technology and Commercialization.

Early life and education Santerre was born in 1960 to parents Roger and Bernadette Santerre. He graduated from Polyvalente Roland-Pépin Santerre became interested in studying applied science after working on oil sands surfactants in Alberta in 1982. He then earned his Master's degree in classical polymer chemistry at University of New Brunswick and his PhD at McMaster University.

Career After earning his PhD in chemical engineering, Santerre joined the University of Ottawa Heart Institute as the lead materials engineer for their artificial heart program. He left Ottawa in 1993 to become a professor of biomaterials at the University of Toronto (U of T). U of T's Innovations and Partnerships Office invested in Santerre's research and helped create the strart-up Interface Biologics Inc. (IBI) to improve the safety and effectiveness of medical devices. Through IBI, Santerre helped produce technologies to make biomaterials more compatible with the human body. One of the first technologies that IBI began producing from Santerre's laboratory was Endex, a surface modifying macromolecule that helps reduce the incidence of clotting. In 2011, Fresenius Medical Care began applying IBI's Endexo technology to dialysis circuits for treating end-stage renal disease.

Santerre became a core faculty member at U of T's Institute of Biomaterials and Biomedical Engineering in 1999 Due to his increasing responsibilities, Santerre stepped down as President of IBI in 2004 but remained on as their Chief Scientific Officer. He was also elected a Fellow of the American Association for the Advancement of Science and received the 2010 Julia Levy Award for successful commercialisation of innovation in Canada from the Society of Chemical Industry.

In February 2018, Santerre was named the Baxter Chair of Health Technology and Commercialization by the University Health Network. Shortly after accepting this new role, Santerre and IBI sold its Endexo surface modification business to Evonik Industries in order to focus more on their Epidel drug delivery platform. In 2020, Santerre received the Lifetime Achievement Award from the Canadian Biomaterials Society.

Personal life Santerre and his wife Shelley Cosman have two children together.